Source: Techstartups

DICE: Eli Lilly acquires biotech firm Dice Therapeutics for $2.4 billion

The pharmaceutical industry encompasses more than just weight-loss drugs. Eli Lilly, a prominent drug-making company, announced on Tuesday that it has agreed to acquire Dice Therapeutics, a specialized firm that focuses on developing oral treatments for autoimmune diseases. The deal, [...]

Read full article »

DICE's Competitors | DICE's News | DICE's Financials

Followers on Owler

Annual Revenue

$100K-5.0M

Employees

25-100

Founder & CEO

Kevin Judice

CEO Approval Rating

90/100

DICE is a California-based biopharmaceutical company that researches and develops novel oral therapeutics for the treatment of chronic autoimmune and inflammatory diseases.